HC Q study #31
See all studies
Late treatment study
Yu et al., Science China Life Sciences, 2020 May 15, 1-7, doi:10.1007/s11427-020-1732-2 (Peer Reviewed)
Low Dose of Hydroxych loroquine Reduces Fatality of Critically Ill Patients With COVID-19
Retrospective, 550 critically ill patients. 19% fatality for HC Q versus 47% for non-HC Q.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.